{"id":451257,"date":"2021-03-04T16:08:29","date_gmt":"2021-03-04T21:08:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451257"},"modified":"2021-03-04T16:08:29","modified_gmt":"2021-03-04T21:08:29","slug":"alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/","title":{"rendered":"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <strong>Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRP<\/strong><br \/>\n          <strong>\u03b1<\/strong><br \/>\n          <strong> antibody conjugated to TLR9 agonist (\u201cSIRP<\/strong><br \/>\n          <strong>\u03b1<\/strong><br \/>\n          <strong> TRAAC\u201d) that delivers targeted immune activation<br \/><\/strong><br \/>\n          \n        <\/li>\n<li>\n          <strong>ALX expands anti-cancer therapeutics pipeline targeting the CD47<\/strong><br \/>\n          <strong> checkpoint pathway<\/p>\n<p><\/strong>\n        <\/li>\n<li>\n          <strong>Collaboration extends Tallac\u2019s pipeline of next generation immunotherapies derived from its Toll-like Receptor Agonist Antibody Conjugate (\u201cTRAAC\u201d) platform<\/p>\n<p><\/strong>\n        <\/li>\n<li>\n          <strong>ALX Oncology to Host\u00a0Conference Call<\/strong><br \/>\n          <strong>\u00a0<\/strong><br \/>\n          <strong>on March 5 at 8:30 a.m. EST<\/strong>\n        <\/li>\n<\/ul>\n<p>BURLINGAME, Calif., March  04, 2021  (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc. (\u201cTallac\u201d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced a collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Under the terms of the agreement, ALX Oncology and Tallac will share equally in the cost of research and development and any profits or losses incurred.<\/p>\n<p>The collaboration builds on ALX Oncology\u2019s expertise in developing therapies that block the CD47 checkpoint pathway and expands its immuno-oncology pipeline. The collaboration also extends Tallac\u2019s pipeline of next generation immunotherapies derived from its novel Toll-like Receptor Agonist Antibody Conjugate (\u201cTRAAC\u201d) platform. The companies will leverage their respective scientific and technical expertise to advance an anti-SIRP\u03b1 antibody conjugated to a Toll-like receptor 9 (\u201cTLR9\u201d) agonist for targeted activation of both the innate and adaptive immune systems.<\/p>\n<p>\u201cWe are excited to partner with ALX Oncology in the development of next-generation breakthrough cancer immunotherapies,\u201d said Hong I. Wan, Ph.D., President, Chief Executive Officer and co-founder of Tallac. \u201cTLR9 agonists are a class of immunotherapy that generate both innate and adaptive immune responses which may produce robust and durable anti-cancer immunity for patients with advanced-stage cancers. While intratumoral TLR9 agonists have clinically validated this pathway, systemic administration has been unsuccessful, limiting clinical utility in broader patient populations. With Tallac\u2019s TRAAC technology, we now have a way to target this pathway systemically, which could expand the clinical benefit to a much broader patient population. To date, we have generated promising preclinical data with multiple TRAAC molecules that demonstrates the potential of this pathway. The goal of our collaboration with ALX Oncology is to advance SIRP\u03b1 TRAAC, a systemically delivered TLR9 agonist targeting dendritic cells via SIRP\u03b1 receptors, enabling a powerful innate and adaptive anti-tumor immune response.\u201d<\/p>\n<p>\u201cCollaborating with Tallac and their novel TRAAC platform broadens ALX Oncology\u2019s therapeutic strategies to activate the innate immune system and SIRP\u03b1 TRAAC complements our lead product candidate, ALX148,\u201d said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. \u201cWhile ALX148 is an antagonistic molecule designed to maximize the activity of a wide array of anticancer agents by the blockade of the CD47 myeloid checkpoint, SIRP\u03b1 TRAAC is an agonistic molecule that directly activates dendritic cells and enables a coordinated innate and adaptive immune response against cancer. Since SIRP\u03b1 is expressed on both dendritic cells and a range of tumor types, SIRP\u03b1 TRAAC may enable an effective immune activation response in advanced cancer settings. We are excited about this potentially transformative approach and the possible benefits to patients that are in need of new treatment options.\u201d<\/p>\n<p><strong>Conference Call on March 5\u00a0at 8:30 a.m. EST<\/strong><\/p>\n<p>ALX Oncology and Tallac will host a conference call on Friday, March 5, 2021 at 8:30 a.m. EST to further discuss the collaboration.<\/p>\n<p>To access the conference call, please dial (844) 467-7655 (local) or (409) 983-9840 (international) at least 10 minutes prior to the start time and refer to conference ID 4117088. Presentation slides will be available to download under \u201cNews &amp; Events\u201d (see \u201cEvents\u201d) in the investors section of the ALX Oncology website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sMLRTPkVXZXfO7OOrOGP6QvkA1kxnQqEjLDAQ-AlWwTPP4pUnSXURbVLQ3Bo4nhq6_yf2yXqiroi9zsQxLLwq-MYGIff9-CxrJkZRmug-8E=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.alxoncology.com<\/a>. \u00a0<\/p>\n<p><strong>About ALX Oncology<\/strong><br \/>ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology\u2019s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sMLRTPkVXZXfO7OOrOGP6ZDcUTVlTVY6vH6-KQ3FZ-ESBq4bvKglS8S6Rc-PexS-8xMWhvP3a8WOAFuz8e-Uc4mIibMfUSapN_IP7_6JQbM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.alxoncology.com<\/a>.<\/p>\n<p>\n        <strong>About Tallac<\/strong><br \/>\n        <br \/>Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac\u2019s pipeline of immunotherapy candidates are derived from the company\u2019s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8GAuay12Ig_1eBj3WmhiZHAP2dHvdc4Tro221tGLyU3EsIlf_W8mlx7EhC1FyEFGU3WKUpFgKEPbx2x1oyHXwSTONk10ydZ9bj2pL0ea5KxIga2V9W8T4x6ViIDiNEnt\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.tallactherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology\u2019s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology\u2019s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the expectations of the collaboration with Tallac and the beneficial characteristics and potential therapeutic effects of SIRP\u03b1 TRAAC. These and other risks are described more fully in ALX Oncology\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including ALX Oncology\u2019s Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020, and other documents ALX Oncology subsequently files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b6cf3681-44c6-44ab-90b9-8e509d8e35da\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>ALX Oncology\r\n\r\nInvestor Contact:\r\nPeter Garcia\r\nChief Financial Officer, ALX Oncology\r\n(650) 466-7125 Ext. 113\r\npeter@alxoncology.com\r\n\r\nArgot Partners\r\n(212) 600-1902\r\nalxoncology@argotpartners.com\r\n\r\nMedia Contact:\r\nKaren Sharma\r\nMacDougall\r\n(781) 235-3060\r\nalx@macbiocom.com\r\n\r\nTallac Therapeutics\r\n\r\nMedia Contact:\r\nTara Cooper\r\nThe Grace Communication Group\r\n(650) 303-7306\r\ntara@gracegroup.us<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRP \u03b1 antibody conjugated to TLR9 agonist (\u201cSIRP \u03b1 TRAAC\u201d) that delivers targeted immune activation ALX expands anti-cancer therapeutics pipeline targeting the CD47 checkpoint pathway Collaboration extends Tallac\u2019s pipeline of next generation immunotherapies derived from its Toll-like Receptor Agonist Antibody Conjugate (\u201cTRAAC\u201d) platform ALX Oncology to Host\u00a0Conference Call \u00a0 on March 5 at 8:30 a.m. EST BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc. (\u201cTallac\u201d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451257","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRP \u03b1 antibody conjugated to TLR9 agonist (\u201cSIRP \u03b1 TRAAC\u201d) that delivers targeted immune activation ALX expands anti-cancer therapeutics pipeline targeting the CD47 checkpoint pathway Collaboration extends Tallac\u2019s pipeline of next generation immunotherapies derived from its Toll-like Receptor Agonist Antibody Conjugate (\u201cTRAAC\u201d) platform ALX Oncology to Host\u00a0Conference Call \u00a0 on March 5 at 8:30 a.m. EST BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc. (\u201cTallac\u201d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced &hellip; Continue reading &quot;ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T21:08:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics\",\"datePublished\":\"2021-03-04T21:08:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/\"},\"wordCount\":1015,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/\",\"name\":\"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=\",\"datePublished\":\"2021-03-04T21:08:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics - Market Newsdesk","og_description":"Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRP \u03b1 antibody conjugated to TLR9 agonist (\u201cSIRP \u03b1 TRAAC\u201d) that delivers targeted immune activation ALX expands anti-cancer therapeutics pipeline targeting the CD47 checkpoint pathway Collaboration extends Tallac\u2019s pipeline of next generation immunotherapies derived from its Toll-like Receptor Agonist Antibody Conjugate (\u201cTRAAC\u201d) platform ALX Oncology to Host\u00a0Conference Call \u00a0 on March 5 at 8:30 a.m. EST BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc. (\u201cTallac\u201d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced &hellip; Continue reading \"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T21:08:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics","datePublished":"2021-03-04T21:08:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/"},"wordCount":1015,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/","name":"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=","datePublished":"2021-03-04T21:08:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzA2OCM0MDQ0NDIzIzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immunotherapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451257"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451257\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}